Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Progression Free Survival 1Hormone Refractory Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

Etoposide 23Cisplatin 15Carboplatin 13Irinotecan 12apatinib 11anlotinib 10durvalumab 7Topotecan 6toripalimab 4surufatinib 4sintilimab 4atezolizumab 4Temozolomide 4Drug Therapy 4tislelizumab 3lobaplatin 3camrelizumab 3Simvastatin 3Radiotherapy 3Ifosfamide 3Albumin-Bound Paclitaxel 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2olaparib 2niraparib 2isophosphamide mustard 2avelumab 2X-Rays 2Platinum 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Small Cell Lung Carcinoma × PE regimen × Clear all
NCT04996771 2022-11-14

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Sun Yat-sen University

Phase 1/2 Unknown
88 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡